A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2019
Price : $35 *
At a glance
- Drugs Guadecitabine (Primary) ; Cyclophosphamide; Tumour cell vaccine-GVAX
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 08 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 18 Oct 2018 Status changed from recruiting to active, no longer recruiting.